Although most of the NSCLC patients who have sensitive EGFR-mutations initially experience a good response to EGFR-TKI, acquired resistance inevitably occurs which leads to a progression of the disease [9, 10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.